[Problems in the current target therapy of malignancies].
Stukov
A N
AN
Gershanovich
M L
ML
Filov
V A
VA
Imianitov
E N
EN
D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001379:Azathioprine / Q000494:pharmacology; D001549:Benzamides; D000068258:Bevacizumab; D000068818:Cetuximab; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D000068877:Imatinib Mesylate; D009369:Neoplasms / Q000188:drug therapy*; D010793:Phthalazines / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology; D000069283:Rituximab; D012717:Sesquiterpenes / Q000494:pharmacology; D045789:Sesquiterpenes, Guaiane; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D001549:Benzamides; D010793:Phthalazines; D010879:Piperazines; D011725:Pyridines; D011743:Pyrimidines; D011799:Quinazolines; D015363:Quinolones; D012717:Sesquiterpenes; D045789:Sesquiterpenes, Guaiane; D000068258:Bevacizumab; D000074323:Alemtuzumab; D000069283:Rituximab; C422802:ibritumomab tiuxetan; C404768:vatalanib; C083346:arglabin; D000068877:Imatinib Mesylate; D000069347:Erlotinib Hydrochloride; C119496:tositumomab I-131; C402769:tipifarnib; D001379:Azathioprine; D000068878:Trastuzumab; D000068818:Cetuximab; D000077156:Gefitinib